Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ELAB | Pmgc | $5.13 | -$8.87 | -63.36% | 11.4M | $7.6M | $1.62$466.20 |
| SST | System1 | $4.02 | -$1.20 | -23.02% | 1.5M | $42M | $1.35$15.00 |
| CDT | Cdt Equity | $4.23 | -$0.87 | -17.06% | 65.7K | $902K | $4.11$4,200.00 |
| RVYL | Ryvyl | $4.93 | -$0.86 | -14.79% | 116.3K | $7.3M | $4.14$81.55 |
| INBS | Intelligent Bio Solutions | $2.67 | -$0.46 | -14.58% | 999.6K | $6.2M | $2.56$24.90 |
| CYCN | Cyclerion Therapeutics | $5.45 | -$0.93 | -14.58% | 6.3M | $25M | $1.03$8.48 |
| RENX | RenX Enterprises | $2.23 | -$0.38 | -14.54% | 825.1K | $6.1M | $1.42$47.20 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $41.21 | -$5.44 | -11.66% | 351.6K | - | $38.62$706.00 |
| EEIQ | EpicQuest Education Group International | $9.35 | -$1.23 | -11.63% | 401.8K | $16M | $1.90$27.84 |
| FGI | Fgi Industries | $4.40 | -$0.57 | -11.47% | 26.7K | $9.5M | $2.28$12.62 |
| MODD | Modular Medical | $4.80 | -$0.58 | -10.78% | 28.4K | $752M | $3.55$34.50 |
| ALEC | Alector | $2.29 | -$0.24 | -9.49% | 282.4K | $279M | $0.87$3.40 |
| FBYD | Falcon's Beyond Global | $11.02 | -$1.13 | -9.30% | 511 | $588M | $3.71$29.02 |
| ARMG | Themes ETF Trust - Leverage Shares 2x Long Arm Daily ETF | $9.30 | -$0.90 | -8.82% | 424K | - | $4.28$17.56 |
| PSTV | Plus Therapeutics | $3.69 | -$0.21 | -5.26% | 311.6K | $668M | $3.23$30.50 |
Related Articles
Featured Article
Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring
Dan Caplinger|Jul 2, 2021
One of these companies is making big waves.
What Company Will Eli Lilly Buy Next?
David Haen|Jan 23, 2020
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
Biotech’s Year-End To-Do List
David Haen|Dec 7, 2019
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now
David Haen|Nov 9, 2019
No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.
Are There Good Investments Among 2019's Biotech IPOs?
David Haen|Oct 2, 2019
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
